Desperate measures: Shire sells Dermagraft for nothing up front
This article was originally published in Scrip
Executive Summary
Shire has signed a deal for its loss-making skin substitute product Dermagraft that effectively sees it giving the product away just to remove the drag on its earnings.
You may also be interested in...
Scrip Asks…What Does 2021 Hold For Biopharma? Part 1: Tackling COVID-19
Industry leaders share their expectations around COVID-19 for the coming year. Further product development and vaccine rollout will be key themes in 2021. Equitable supply and addressing the mental health challenges associated with lockdowns also loom large.
Sanofi’s Latest Credit Facility Offers Win-Win Model For Pharma And Society
French phama pioneers sustainable finance in pharma with $8bn in new credit facilities tied to polio eradication and carbon reduction.
Sanofi’s New Loan Offers Win-Win Model For Pharma And Society
Sanofi pioneers sustainable finance in pharma with $8bn in new credit facilities tied to polio eradication and carbon reduction.
Need a specific report? 1000+ reports available
Buy Reports